NICE no for Novartis' Lucentis is good news for Allergan's Ozurdex
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, is poised to decline Novartis' VEGF receptor agonist Lucentis (ranibizumab) for another indication, visual impairment caused by macular oedema secondary to central or branch retinal vein occlusion (C/BRVO). Allergan, which markets Ozurdex (dexamethasone implant), recommended by NICE for this indication earlier this year, will likely welcome the news.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.